{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:23:50Z","timestamp":1728620630874},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00120-024-02442-z","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T13:02:24Z","timestamp":1728306144000},"page":"975-976","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aktuelle Entwicklungen zum Urothelkarzinom","Current developments in urothelial carcinoma"],"prefix":"10.1007","volume":"63","author":[{"given":"G\u00fcnter","family":"Niegisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"issue":"10","key":"2442_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T et\u00a0al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N\u00a0Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"issue":"21","key":"2442_CR2","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot\u00a0Y et\u00a0al (2023) Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N\u00a0Engl J Med 389(21):1961\u20131971","journal-title":"N Engl J Med"},{"issue":"6_suppl","key":"2442_CR3","first-page":"TPS505\u2013TPS505","volume":"39","author":"T Powles","year":"2021","unstructured":"Powles\u00a0T et\u00a0al (2021) A\u00a0phase\u00a0III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA). Clin Oncol 39(6_suppl):TPS505\u2013TPS505","journal-title":"Clin Oncol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02442-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02442-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02442-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T17:03:03Z","timestamp":1728579783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02442-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":3,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2442"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02442-z","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"7 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.\u00a0Niegisch und M.\u00a0Kramer geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}